ARA-290 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Clinical trials in sarcoidosis-associated small fiber neuropathy and type 2 diabetes showed significant pain reduction and nerve regeneration. A 28-day protocol initiated measurable corneal nerve fiber regrowth. Chronic stress studies showed antidepressant effects comparable to fluoxetine. 4+ completed clinical trials in humans. ARA-290 is investigational. underwent phase ii clinical trials. not fda-approved.
What Does the Research Say About ARA-290?
Clinical trials in sarcoidosis-associated small fiber neuropathy and type 2 diabetes showed significant pain reduction and nerve regeneration. A 28-day protocol initiated measurable corneal nerve fiber regrowth. Chronic stress studies showed antidepressant effects comparable to fluoxetine. 4+ completed clinical trials in humans.
ARA-290 (Erythropoietin-derived tissue-protective peptide) is a Innate repair receptor agonist, anti-inflammatory peptide. Research interest has focused on its potential effects on neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.
What Is the Evidence for ARA-290's Mechanism?
Selectively activates the innate repair receptor (IRR), a CD131/EPOR heterodimer, triggering anti-inflammatory and tissue-protective signaling without any effect on red blood cell production. Suppresses microglia activation and pro-inflammatory cytokine release. Dose-dependently reduces neuropathic pain through central inflammation suppression.
These pathways have been identified through in vitro studies, animal models, and where available, human trials.
Are There Human Clinical Trials for ARA-290?
Clinical trials in sarcoidosis-associated small fiber neuropathy and type 2 diabetes showed significant pain reduction and nerve regeneration. A 28-day protocol initiated measurable corneal nerve fiber regrowth. Chronic stress studies showed antidepressant effects comparable to fluoxetine. 4+ completed clinical trials in humans.
The gap between preclinical promise and clinical validation remains the biggest challenge in peptide research. However, ARA-290 has shown encouraging results.
What Does the Safety Research Show?
Safe profile in multiple clinical trials. Minimal reported adverse events. Occasional mild injection site reactions. No serious safety concerns identified across diabetes, sarcoidosis, and neuropathy patient populations.
ARA-290 is investigational. underwent phase ii clinical trials. not fda-approved.
What Makes ARA-290 Unique in Research?
The only EPO-derived peptide that completely decouples tissue protection from red blood cell production — providing nerve regeneration without any hematologic effects.
This differentiator is important because it means ARA-290 fills a role that other compounds in its class may not fully replicate.
Bottom Line on ARA-290 Research
The evidence base for ARA-290 is growing. Key research areas include neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.
Stay current with PubMed searches for ARA-290 for the latest publications.
Complete Guide
ARA-290 : Benefits, Dosage, Side Effects & Research
Related Reading
- ARA-290 Dosage Guide
- ARA-290 Benefits
- ARA-290 Side Effects
- ARA-290 Stacking Guide
- ARA-290 Cycle Guide
- BPC-157 Complete Guide
Calculate Your ARA-290 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for ARA-290.
Open Calculator →Research-Grade Sourcing
If you're going to research ARA-290, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is ARA-290?
ARA-290 (Erythropoietin-derived tissue-protective peptide) is a Innate repair receptor agonist, anti-inflammatory peptide. Synthetic 11-amino acid peptide engineered from the tissue-protective domain of erythropoietin (EPO). It is researched for neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.
What is the recommended ARA-290 dosage?
Common dosages: 2-4 mg daily administered once daily via subcutaneous injection. Cycle length: 28 days typical; 8-16 weeks for extended response. Half-life: approximately 24 hours. Use our peptide calculator for exact reconstitution math.
What are the side effects of ARA-290?
Safe profile in multiple clinical trials. Minimal reported adverse events. Occasional mild injection site reactions. No serious safety concerns identified across diabetes, sarcoidosis, and neuropathy patient populations.
Is ARA-290 safe?
ARA-290 has shown a preliminary safety profile in research. Investigational. Underwent Phase II clinical trials. Not FDA-approved. All research should follow appropriate safety protocols.